Literature DB >> 7593610

Glucocorticoid-suppressible hyperaldosteronism and adrenal tumors occurring in a single French pedigree.

L Pascoe1, X Jeunemaitre, M C Lebrethon, K M Curnow, C E Gomez-Sanchez, J M Gasc, J M Saez, P Corvol.   

Abstract

Glucocorticoid-suppressible hyperaldosteronism is a dominantly inherited form of hypertension believed to be caused by the presence of a hybrid CYP11B1/CYP11B2 gene which has arisen from an unequal crossing over between the two CYP11B genes in a previous meiosis. We have studied a French pedigree with seven affected individuals in which two affected individuals also have adrenal tumors and two others have micronodular adrenal hyperplasia. One of the adrenal tumors and the surrounding adrenal tissue has been removed, giving a rare opportunity to study the regulation and action of the hybrid gene causing the disease. The hybrid CYP11B gene was demonstrated to be expressed at higher levels than either CYP11B1 or CYP11B2 in the cortex of the adrenal by RT-PCR and Northern blot analysis. In situ hybridization showed that both CYP11B1 and the hybrid gene were expressed in all three zones of the cortex. In cell culture experiments hybrid gene expression was stimulated by ACTH leading to increased production of aldosterone and the hybrid steroids characteristic of glucocorticoid-suppressible hyperaldosteronism. The genetic basis of the adrenal pathologies in this family is not known but may be related to the duplication causing the hyperaldosteronism.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7593610      PMCID: PMC185874          DOI: 10.1172/JCI118279

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  35 in total

1.  Hereditary hypertension caused by chimaeric gene duplications and ectopic expression of aldosterone synthase.

Authors:  R P Lifton; R G Dluhy; M Powers; G M Rich; M Gutkin; F Fallo; J R Gill; L Feld; A Ganguly; J C Laidlaw
Journal:  Nat Genet       Date:  1992-09       Impact factor: 38.330

2.  Mutations in the human CYP11B2 (aldosterone synthase) gene causing corticosterone methyloxidase II deficiency.

Authors:  L Pascoe; K M Curnow; L Slutsker; A Rösler; P C White
Journal:  Proc Natl Acad Sci U S A       Date:  1992-06-01       Impact factor: 11.205

3.  Human cultured adrenal fasciculata-reticularis cells are targets for angiotensin-II: effects on cytochrome P450 cholesterol side-chain cleavage, cytochrome P450 17 alpha-hydroxylase, and 3 beta-hydroxysteroid-dehydrogenase messenger ribonucleic acid and proteins and on steroidogenic responsiveness to corticotropin and angiotensin-II.

Authors:  M C Lebrethon; C Jaillard; G Defayes; M Begeot; J M Saez
Journal:  J Clin Endocrinol Metab       Date:  1994-05       Impact factor: 5.958

4.  Regulation of corticotropin receptor number and messenger RNA in cultured human adrenocortical cells by corticotropin and angiotensin II.

Authors:  M C Lebrethon; D Naville; M Begeot; J M Saez
Journal:  J Clin Invest       Date:  1994-04       Impact factor: 14.808

5.  Hypertension, increased aldosterone secretion and low plasma renin activity relieved by dexamethasone.

Authors:  D J Sutherland; J L Ruse; J C Laidlaw
Journal:  Can Med Assoc J       Date:  1966-11-26       Impact factor: 8.262

6.  The chimeric gene linked to glucocorticoid-suppressible hyperaldosteronism encodes a fused P-450 protein possessing aldosterone synthase activity.

Authors:  K Miyahara; T Kawamoto; Y Mitsuuchi; K Toda; H Imura; R D Gordon; Y Shizuta
Journal:  Biochem Biophys Res Commun       Date:  1992-12-15       Impact factor: 3.575

7.  Gene expression and tissue localization of the two isoforms of angiotensin I converting enzyme.

Authors:  M Sibony; J M Gasc; F Soubrier; F Alhenc-Gelas; P Corvol
Journal:  Hypertension       Date:  1993-06       Impact factor: 10.190

8.  Glucocorticoid-suppressible hyperaldosteronism results from hybrid genes created by unequal crossovers between CYP11B1 and CYP11B2.

Authors:  L Pascoe; K M Curnow; L Slutsker; J M Connell; P W Speiser; M I New; P C White
Journal:  Proc Natl Acad Sci U S A       Date:  1992-09-01       Impact factor: 11.205

Review 9.  Genetic recombination as a cause of inherited disorders of aldosterone and cortisol biosynthesis and a contributor to genetic variation in blood pressure.

Authors:  L Pascoe; K M Curnow
Journal:  Steroids       Date:  1995-01       Impact factor: 2.668

10.  Mutations in the CYP11B1 gene causing congenital adrenal hyperplasia and hypertension cluster in exons 6, 7, and 8.

Authors:  K M Curnow; L Slutsker; J Vitek; T Cole; P W Speiser; M I New; P C White; L Pascoe
Journal:  Proc Natl Acad Sci U S A       Date:  1993-05-15       Impact factor: 11.205

View more
  14 in total

Review 1.  Acute and chronic regulation of aldosterone production.

Authors:  Namita G Hattangady; Lawrence O Olala; Wendy B Bollag; William E Rainey
Journal:  Mol Cell Endocrinol       Date:  2011-08-04       Impact factor: 4.102

Review 2.  The epithelial sodium channel in hypertension.

Authors:  D G Warnock
Journal:  Curr Hypertens Rep       Date:  1999 Apr-May       Impact factor: 5.369

3.  Development of monoclonal antibodies against human CYP11B1 and CYP11B2.

Authors:  Celso E Gomez-Sanchez; Xin Qi; Carolina Velarde-Miranda; Maria W Plonczynski; C Richard Parker; William Rainey; Fumitoshi Satoh; Takashi Maekawa; Yasuhiro Nakamura; Hironobu Sasano; Elise P Gomez-Sanchez
Journal:  Mol Cell Endocrinol       Date:  2013-12-08       Impact factor: 4.102

Review 4.  Immunohistochemistry of aldosterone synthase leads the way to the pathogenesis of primary aldosteronism.

Authors:  Koshiro Nishimoto; Minae Koga; Tsugio Seki; Kenji Oki; Elise P Gomez-Sanchez; Celso E Gomez-Sanchez; Mitsuhide Naruse; Tomokazu Sakaguchi; Shinya Morita; Takeo Kosaka; Mototsugu Oya; Tadashi Ogishima; Masanori Yasuda; Makoto Suematsu; Yasuaki Kabe; Masao Omura; Tetsuo Nishikawa; Kuniaki Mukai
Journal:  Mol Cell Endocrinol       Date:  2016-10-14       Impact factor: 4.102

Review 5.  Role of KCNJ5 in familial and sporadic primary aldosteronism.

Authors:  Paolo Mulatero; Silvia Monticone; William E Rainey; Franco Veglio; Tracy Ann Williams
Journal:  Nat Rev Endocrinol       Date:  2012-12-11       Impact factor: 43.330

6.  Angiotensin II triggers expression of the adrenal gland zona glomerulosa-specific 3β-hydroxysteroid dehydrogenase isoenzyme through de novo protein synthesis of the orphan nuclear receptors NGFIB and NURR1.

Authors:  Takumi Ota; Masao Doi; Fumiyoshi Yamazaki; Daisuke Yarimizu; Kazuki Okada; Iori Murai; Hida Hayashi; Sumihiro Kunisue; Yuuki Nakagawa; Hitoshi Okamura
Journal:  Mol Cell Biol       Date:  2014-08-04       Impact factor: 4.272

7.  Improving the diagnosis of 11β-hydroxylase deficiency using home-made MLPA probes: identification of a novel chimeric CYP11B2/CYP11B1 gene in a Sicilian patient.

Authors:  S Menabò; S Boccassini; A Gambineri; A Balsamo; R Pasquali; O Prontera; L Mazzanti; L Baldazzi
Journal:  J Endocrinol Invest       Date:  2015-08-18       Impact factor: 4.256

Review 8.  Aldosterone-producing adenoma and other surgically correctable forms of primary aldosteronism.

Authors:  Laurence Amar; Pierre-François Plouin; Olivier Steichen
Journal:  Orphanet J Rare Dis       Date:  2010-05-19       Impact factor: 4.123

9.  Positron emission tomography imaging of adrenal masses: (18)F-fluorodeoxyglucose and the 11beta-hydroxylase tracer (11)C-metomidate.

Authors:  Georg Zettinig; Markus Mitterhauser; Wolfgang Wadsak; Alexander Becherer; Christian Pirich; Heinrich Vierhapper; Bruno Niederle; Robert Dudczak; Kurt Kletter
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-06-10       Impact factor: 9.236

10.  Invalidation of TASK1 potassium channels disrupts adrenal gland zonation and mineralocorticoid homeostasis.

Authors:  Dirk Heitzmann; Renaud Derand; Stefan Jungbauer; Sascha Bandulik; Christina Sterner; Frank Schweda; Abeer El Wakil; Enzo Lalli; Nicolas Guy; Raymond Mengual; Markus Reichold; Ines Tegtmeier; Saïd Bendahhou; Celso E Gomez-Sanchez; M Isabel Aller; William Wisden; Achim Weber; Florian Lesage; Richard Warth; Jacques Barhanin
Journal:  EMBO J       Date:  2007-11-22       Impact factor: 11.598

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.